All In Biotech

Drug Trial Radar · NCT03884881

Second-generation Sequencing Guides the Treatment of Severe Pneumonia

The Role of Second-generation Sequencing in the Treatment of Severe Pneumonia With Initial Treatment Failure

Last checked: Nov 20, 2026Latest source record: Mar 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

400

Actual

Start

Jan 1, 2018

Primary completion

Dec 1, 2019

Study completion Dec 1, 2019

Sponsor

Lead sponsor
Xiangya Hospital of Central South UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Investigators plan to conduct the participants level, 1:1 randomized trial at the Central ICU and respiratory ICU of Xiangya Hospital in Changsha, China, from January 1, 2018 to December 31, 2019. Participants with initial diagnosis of severe pneumonia will be first treated with empiric therapy, after 48-72 hours, the participants's condition will be evaluated, and participants who will have been initially cured and died should be excluded.The participants who will have failed the initial treatment will be then randomly divided into two groups: the NGS group and the conventional treatment group. Bronchoalveolar lavage fluid will be taken by bedside bronchoscopy when the participants underwent nasal high-flow oxygen therapy, non-invasive ventilation, and invasive ventilation,or venous blood will be taken for examination. Participants in the NGS group will be tested for both NGS and conventional pathogens, however, the routine group will be only routinely tested. According to the pathogen results, participants with non-severe pneumonia will be excluded, and medication should be adjusted under the joint guidance of infectious and respiratory specialists. Then investigators will compare the first outcome: 28-day mortality, and secondary outcome: ICU hospitalization time, mechanical ventilation time, Hospitalization costs, antibiotic use costs, SOFA scores, CURB-65 scores, APACHE scores, and other clinical indicators.

Conditions

  • Pneumonia
  • Metagenomic Next Generation Sequencing

Interventions

  • metagenomic next generation sequencingDiagnostic test

    Pathogens in the NGS group will be tested by NGS,then according the NGS results, adjust antibiotics

  • Conventional pathogen detectionDiagnostic test

    Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics

  • Meropenem,Imipenem,Caspofene,OsstatDrug

    Meropenem,Imipenem,Caspofene,Osstat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mortalityTime frame: 28 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.